Trial · NCT00166114

Depression, Epinephrine, and Platelet Function

NCT00166114, Phase 4, Completed, Emory University; results first posted 2015-07-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Depression, Epinephrine, and Platelet Function. Trials, record NCT00166114. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00166114

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Depression, Epinephrine, and Platelet Function
NCT number: NCT00166114
Status: Completed
Phases: Phase 4
Enrollment: 40 participants, actual
Lead sponsor: Emory University
Conditions: Major Depressive Disorder
Interventions: Escitalopram, Desipramine
First posted: 2005-09-14
Last updated: 2015-07-23
Results first posted: 2015-07-23

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8	Baseline, Week 8	Number of subjects that showed no response, partial response, and response based on scores from baseline and week 8. The 21-item HDRS measures depression severity. The scoring is sum the total of all 21 items to arrive at the total score, with a range of 0 to 60, where higher scores indicated greater severity. Nine items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Eleven items are scored from 0 - 2 (0 = absent and 2 = severe). The last item is scored on a 4-point scale of 0-3 (0 = absent and 3 = severe). The HDRS at week 8 was compared to the baseline HDRS and each participant's response was calculated using the below table: No Response = \< 25% change in Depression Rating Scale Score Partial Responder = \< 50% to \>25% change in Depression Rating Scale Score Responder = 50% or greater change in Depression Rating Scale Score

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8	Baseline, Week 8		participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8	Escitalopram	Response	5	participants
Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8	Desipramine	Response	9	participants
Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8	Escitalopram	No or Partial Response	2	participants
Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8	Desipramine	No or Partial Response	4	participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Escitalopram	21
Overall Study	STARTED	Desipramine	19
Overall Study	COMPLETED	Escitalopram	7
Overall Study	COMPLETED	Desipramine	13
Overall Study	NOT COMPLETED	Escitalopram	14
Overall Study	NOT COMPLETED	Desipramine	6

Source ClinicalTrials.gov

Adverse events40

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Dry Mouth	Skin and subcutaneous tissue disorders	Escitalopram	2	21
other	Dry Mouth	Skin and subcutaneous tissue disorders	Desipramine	2	19
other	Orthostatic Tachycardia	Cardiac disorders	Escitalopram	0	21
other	Orthostatic Tachycardia	Cardiac disorders	Desipramine	1	19
other	Rash	Skin and subcutaneous tissue disorders	Escitalopram	0	21
other	Rash	Skin and subcutaneous tissue disorders	Desipramine	1	19
other	Pruritis	Skin and subcutaneous tissue disorders	Escitalopram	0	21
other	Pruritis	Skin and subcutaneous tissue disorders	Desipramine	1	19
other	Heartburn	Gastrointestinal disorders	Escitalopram	1	21
other	Heartburn	Gastrointestinal disorders	Desipramine	0	19

1 to 10 of 40Source ClinicalTrials.gov

See all 40 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Escitalopram
Total, all-cause mortality	Desipramine
Total, other adverse events	Escitalopram	13	21
Total, other adverse events	Desipramine	18	19
Total, serious adverse events	Escitalopram	1	21
Total, serious adverse events	Desipramine	0	19

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
15953798	BACKGROUND	PubMed
18378867	RESULT	PubMed
18619999	BACKGROUND	PubMed
22966422	BACKGROUND	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01HL065523	Depression, Epinephrine, Serotonin, &Platelet Function	MUSSELMAN, DOMINIQUE L.	EMORY UNIVERSITY	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	2002 to 2005

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Escitalopram vs Desipramine: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00166114

GET https://conductscience.org/api/trials/v1/NCT00166114/events?page=2

API reference For AI assistants